Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz

Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.

Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal worth around $2.1 billion with drug giant Novo Nordisk for the zaltenibart, a phase 2 asset of the former, in development for rare blood and kidney disorders. Omeros is receiving $340 million in upfront and near-term milestone payments, up to $2.1 billion in milestone payments, plus tiered royalties on potential net sales.

Omeros Corporation (NASDAQ:OMER) continues to receive bullish reviews from analysts on Wall Street. HC Wainwright has a Buy rating on the shares with a price target of $9. The company’s lead product candidate is the Narsoplimab for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy. It also develops OMS1029, which has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 and lectin pathway disorders.

Omeros Corporation (NASDAQ:OMER) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

While we acknowledge the potential of OMER as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term